Phase II Trial of Bortezomib Alone or in Combination with Irinotecan in Patients with Adenocarcinoma of the Gastroesophageal Junction or Stomach

PURPOSE: To determine the effectiveness of bortezomib plus irinotecan and bortezomib alone in patients with advanced gastroesophageal junction (GEJ) and gastric adenocarcinoma. We also sought to explore the effect of these therapeutics on tumor and normal gene expression in vivo. METHODS: Forty-one...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ocean, Allyson J., Christos, Paul, Sparano, Joseph A., Shah, Manish A., Yantiss, Rhonda K., Cheng, Jonathan, Lin, Juan, Papetti, Michael, Matulich, Dan, Schnoll-Sussman, Felice, Besanceney-Webler, Christen, Xiang, Jenny, Ward, Maureen, Dilts, Kaili Temple, Keresztes, Roger, Holloway, Shannon, Chen, Eric X., Wright, John J., Lane, Maureen E.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4047141/
https://ncbi.nlm.nih.gov/pubmed/24526575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0070-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars